ArticleThe Journal of antimicrobial chemotherapy2023
Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects.
Article in The Journal of antimicrobial chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Pooled it
- Simultaneous quantification of linezolid and its metabolites (PNU-142300 and PNU-142586) in oral fluid and capillary blood by UPLC-MS/MS: method validation and clinical application using non-invasive sampling techniques.Journal of translational medicine · 2026Article
- Prolonged linezolid therapy induces progressive mitochondrial dysfunction in human peripheral blood mononuclear cells.Journal of translational medicine · 2026Article
- Real-World Comparison of Intravenous vs. Oral Antimicrobial Therapy for Bone and Joint Infections.Pharmacy (Basel, Switzerland) · 2026Article
- Severe methicillin-resistant Staphylococcus aureus (MRSA) sepsis with hematogenous pulmonary abscesses and humeral osteomyelitis in a previously healthy child: a case report.BMC infectious diseases · 2026Article
- Linezolid Related Adverse Effects in Different Populations: A Review.Current drug safety · 2026Review
- Decellularized bone extracellular matrix embedded with PLGA-linezolid microparticles for infected bone regeneration.Biomedical engineering online · 2025Article
- The Impact of a Structured Outpatient Parenteral Antimicrobial Therapy (OPAT) Programme on Quality of Care, Optimisation of Antimicrobial Use, and Healthcare Costs: A Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2025Article
- Protective Effect of Exogenous Adenosine Triphosphate Against Ocular Toxicity of Linezolid in Rats.Life (Basel, Switzerland) · 2025Article
- Periorbital and Central Nervous System Infection Due toMicroorganisms · 2025Article
- The Protective Effect of Thiamine and Thiamine Pyrophosphate Against Linezolid-Induced Oxidative Liver Damage and Lactic Acidosis in Rats.Antioxidants (Basel, Switzerland) · 2025Article
- Risk Assessment of Linezolid-Associated Neurological Adverse Drug Reactions Based on the Food and Drug Administration Adverse Event Reporting System Database.Journal of multidisciplinary healthcare · 2025Article
- Oral tetracyclines for bone and joint infections: what do we know?Journal of bone and joint infection · 2025Review
- Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records.Frontiers in pharmacology · 2025Article
- β-tricalcium phosphate/calcium sulfate loaded with contezolid acefosamil (MRX-4) for antimicrobial potency, prevention and killing efficacy of MRSA biofilm.Frontiers in pharmacology · 2025Article
- Clinical Features and Treatment Differences Among Tuberculous, Brucellosis, and Pyogenic Spondylitis: A Cohort Study.Infection and drug resistance · 2025Article
- Comparison of the results of medical approach and surgical approach of septic arthritis in native joints: a single-center retrospective study.BMC musculoskeletal disorders · 2024Article
- Severe Optic Neuropathy Induced by Very Prolonged Tedizolid as Suppressive Therapy: Description of a Case Report and Implication for Better Assessment.Open forum infectious diseases · 2024Article
- Modern Microbiological Methods to Detect Biofilm Formation in Orthopedy and Suggestions for Antibiotic Therapy, with Particular Emphasis on Prosthetic Joint Infection (PJI).Microorganisms · 2024Review
- Repurposing of anti-malarial drugs for the treatment of tuberculosis: realistic strategy or fanciful dead end?Malaria journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAntibiotic treatment for bone and joint infections generally lasts for 6 weeks or longer. Linezolid may be a good option for treating bone and joint infections, but there is an increased risk of potential serious adverse drug events (ADEs) when used for more than 28 days. The aim of this study was to obtain detailed information on the type and time to occurrence of the patient-reported ADEs, the dynamics of haematopoiesis over time, and the reasons for early discontinuation of linezolid when used for an intended maximum duration of 12 weeks.
methodsThis single-centre retrospective study was conducted at the Sint Maartenskliniek in The Netherlands. Patients were included if they were planned to use linezolid for more than 28 days. The main reason for discontinuation of linezolid, the ADE according to the Naranjo score, and the time to occurrence of ADEs were analysed.
resultsAmong 78 patients, drug toxicity led to early discontinuation of linezolid in 11 (14%) patients before and nine (12%) after 28 days of therapy. The median treatment duration was 42 days. Gastrointestinal intolerance (42%) and malaise (32%) were the most common ADEs. In 75% of the cases the ADE occurred within 28 days of therapy. Sixty-seven patients were able to continue linezolid beyond 28 days, 87% of whom completed therapy as scheduled. Severe cytopenia, according to the Common Terminology Criteria for Adverse events (CTCA), was observed in four patients and was reversible after discontinuation of linezolid. One patient suffered optic neuropathy related to linezolid use.
conclusionsLinezolid could be considered an alternative option to the current standard of IV glycopeptides for the treatment of bone and joint infection for up to 12 weeks. If patients pass the first 28 days of therapy, the likelihood of successful completion of therapy is high with a low risk of serious ADEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.